How to Switch from Lorazepam to Diazepam
Convert lorazepam to an equivalent dose of diazepam using a 1:10 ratio (1 mg lorazepam = 10 mg diazepam), then initiate a gradual hyperbolic taper of diazepam over months to years, reducing by approximately 5-10% of the current dose every 1-4 weeks based on withdrawal symptom tolerance.
Conversion Strategy
The switch from lorazepam to diazepam requires careful dose equivalency calculation and cross-titration to prevent withdrawal symptoms:
- Use standard benzodiazepine equivalency: 1 mg lorazepam = 10 mg diazepam 1
- Calculate total daily lorazepam dose and convert to diazepam equivalent
- Consider cross-titration rather than abrupt switching, especially in elderly patients or those with cognitive impairment, as direct switching without overlap can precipitate severe withdrawal including delirium 2
Critical Pitfall to Avoid
Do not perform an abrupt switch without cross-titration. A case report demonstrated that switching directly from lorazepam to diazepam without gradual cross-titration precipitated acute delirium, even at equivalent doses 2. The mechanism involves the need for N-desmethyl-diazepam (diazepam's long-acting metabolite) to accumulate to therapeutic levels before completely discontinuing lorazepam.
Recommended Cross-Titration Approach
Week 1-2: Introduce diazepam at 50-75% of the calculated equivalent dose while maintaining full lorazepam dose. This allows diazepam and its active metabolite to begin accumulating 2.
Week 2-3: Gradually reduce lorazepam by 25% while maintaining or slightly increasing diazepam to full equivalent dose.
Week 3-4: Continue tapering lorazepam by another 25-50% while monitoring for withdrawal symptoms.
Week 4+: Complete lorazepam discontinuation once diazepam levels have stabilized.
Diazepam Tapering Protocol
Once fully converted to diazepam, the FDA label provides general guidance 3, but recent pharmacological evidence demands a more sophisticated approach:
Hyperbolic (Proportionate) Tapering is Superior to Linear Tapering
Use hyperbolic dose reductions (5-10% of the current dose) rather than fixed linear reductions 4. The relationship between benzodiazepine dose and GABA-A receptor occupancy is hyperbolic—steeply inclining at low doses and flattening at higher doses. Linear reductions (e.g., 2 mg every 2 weeks) produce exponentially larger changes in receptor occupancy as doses decrease, explaining why patients often tolerate initial reductions but experience severe withdrawal at lower doses 4.
Specific Tapering Schedule
- Initial phase (doses >10 mg): Reduce by 10% of current dose every 1-2 weeks
- Middle phase (doses 5-10 mg): Reduce by 5-10% of current dose every 2-4 weeks
- Final phase (doses <5 mg): Reduce by 5% of current dose every 2-4 weeks, potentially extending to monthly reductions 4, 5
The final doses may need to be extremely small—as low as 0.2 mg diazepam or less—to ensure the last step to zero is not pharmacologically larger than previous tolerated reductions 4. Use liquid formulations or compounded preparations to achieve these micro-doses.
Timeline Expectations
Plan for months to years, not weeks 4, 5. The 2025 Joint Clinical Practice Guideline emphasizes that benzodiazepine tapering is "a marathon, not a sprint" 5. Slower tapering over extended periods has higher success rates than rapid tapers over days or weeks.
Monitoring and Dose Adjustments
- Assess withdrawal symptoms at each dose reduction using standardized tools
- If withdrawal symptoms emerge: Pause the taper or increase back to the previous tolerated dose, then resume tapering more slowly 6, 3
- Higher-risk patients (elderly, hepatic/renal dysfunction, longer duration of use, higher doses) require slower tapers 1, 6, 3
Pharmacokinetic Considerations
Both lorazepam and diazepam are hepatically metabolized, but with important differences 1:
- Lorazepam: Glucuronide conjugation; elimination prolonged in renal failure
- Diazepam: Cytochrome P450 metabolism producing active metabolites (N-desmethyl-diazepam) that accumulate in renal dysfunction; longer half-life allows for smoother withdrawal
Elderly patients have significantly reduced clearance of both medications and are more sensitive to sedative effects, requiring lower initial doses and slower tapers 1, 3.
Withdrawal Symptom Management
Both FDA labels warn that abrupt discontinuation can precipitate life-threatening withdrawal reactions including seizures 6, 3. Common withdrawal symptoms include:
- Anxiety, agitation, restlessness
- Tremor, muscle spasms
- Insomnia
- Perceptual disturbances
- In severe cases: seizures, delirium
Protracted withdrawal syndrome can occur with symptoms persisting weeks to over 12 months after discontinuation 6, 3. This necessitates extended monitoring beyond the tapering period.
Special Populations
Patients with cognitive impairment or dementia: Exercise extreme caution with benzodiazepine switching, as these patients show heightened vulnerability to withdrawal-induced delirium 2. Consider maintaining on stable low-dose benzodiazepines rather than attempting discontinuation.
Patients with seizure disorders: Gradual tapering is critical as abrupt withdrawal may increase seizure frequency and severity 3.
Pregnant patients: Late pregnancy use can cause neonatal sedation and withdrawal; however, abrupt discontinuation also carries risks. Coordinate with obstetrics for individualized management 3.
Alternative Approach for Complex Cases
For patients with prior failed tapers, multiple substance use, or severe dependence, consider inpatient management with phenobarbital substitution protocols as an alternative to diazepam 7. However, for most patients, the outpatient diazepam taper described above remains the standard approach.